Table 2.
IC50 (half maximal inhibitory concentration) determination using a cell proliferation assay
| Cell line | Hisopathology | Animal | Cell proliferation IC50⁎ (μM) |
||
|---|---|---|---|---|---|
| HNHA ± Sorafenib | HNHA | Sorafenib | |||
| 8505C | Thyroid cancer: anaplastic | Human | 3.82 (±0.5)* | 17.42 (±0.6) | 10.21 (±0.9) |
| SNU-80 | Thyroid cancer: anaplastic | Human | 0.87 (±1.1)* | 2.28 (±0.4) | 5.14 (±1.1) |
| GSA1 | Thyroid cancer: anaplastic | Human | 8.72 (±0.5)* | 20.14 (±0.5) | 23.45 (±0.6) |
HNHA and sorafenib combination treatment is a lower IC50 than HNHA or sorafenib alone. Each data point represents the mean of 3 independent MTT assays for IC50 performed in triplicate. SD, standard deviation.